142 related articles for article (PubMed ID: 3504088)
1. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
[TBL] [Abstract][Full Text] [Related]
5. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
[TBL] [Abstract][Full Text] [Related]
6. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
9. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
10. Interferon alpha-2a in cutaneous T-cell lymphoma.
Vegna ML; Papa G; Defazio D; Pisani F; Coppola G; De Pità O; Puddu P; Ferranti G; Simoni R; Mandelli F
Eur J Haematol Suppl; 1990; 52():32-5. PubMed ID: 2279544
[TBL] [Abstract][Full Text] [Related]
11. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
12. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?
Papa G; Tura S; Mandelli F; Vegna ML; Defazio D; Mazza P; Zinzani PL; Simoni R; DePita O; Ferranti G
Br J Haematol; 1991 Oct; 79 Suppl 1():48-51. PubMed ID: 1931709
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome.
Kuzel TM; Roenigk HH; Samuelson E; Herrmann JJ; Hurria A; Rademaker AW; Rosen ST
J Clin Oncol; 1995 Jan; 13(1):257-63. PubMed ID: 7799028
[TBL] [Abstract][Full Text] [Related]
14. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy.
Vonderheid EC; Thompson R; Smiles KA; Lattanand A
Arch Dermatol; 1987 Jun; 123(6):757-63. PubMed ID: 3579357
[TBL] [Abstract][Full Text] [Related]
15. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas.
Bunn PA; Ihde DC; Foon KA
Cancer; 1986 Apr; 57(8 Suppl):1689-95. PubMed ID: 3485012
[TBL] [Abstract][Full Text] [Related]
16. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
[TBL] [Abstract][Full Text] [Related]
17. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
18. Alpha recombinant interferon in the treatment of mycosis fungoides (MF).
Tura S; Mazza P; Zinzani PL; Ghetti PL; Poletti G; Gherlinzoni F; Montagnani A; Criscuolo D
Haematologica; 1987; 72(4):337-40. PubMed ID: 3117634
[No Abstract] [Full Text] [Related]
19. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
20. [Rational basis for the use of alfa-2a recombinant interferon in the treatment of mycosis fungoides (MF)].
Mazza P; Bocchia M; Zinzani PL; Gherlinzoni F; Ghetti PL
Haematologica; 1990; 75 Suppl 4():78-81. PubMed ID: 1981571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
